Phase II trial of erlotinib and bevacizumab in patients with advanced upper gastrointestinal cancers
Article 2011 en
Authors
KR
Kristoffer Staal Rohrberg
RO
Rene K Olesen
PP
Per Pfeiffer
Abstract
1 min read
The combination of erlotinib and bevacizumab is well tolerated, however, with low clinical activity in patients with chemoresistant UGI cancer. Some patients do benefit from the therapy, and uPAR forms are potential biomarkers in these patients.
Miguel A. Villalona‐Calero, Everett E. Vokes, Marzia Capelletti, Pasi A. Jänne, Martin J. Edelman, Jeffrey Crawford, Xiaofei Wang, Robert A. Kratzke, Thomas E. Stinchcombe, Lin Gu, Mark A. Socinski, Vincent A. Miller
Olivier Mir, Sylvain Briand, Thierry Lazure, Julien Adam, Rastilav Bahleda, Jean Yves Blay, Andréa Cavalcanti, Ali N. Chamseddine, Aurélie Dutour, Matthieu Faron, L. Haddag, Clémence Hénon, C. Le Péchoux, Antonin Lévy, Carine Ngo, Benjamin Verret, Charles Honoré, Charles Court, Axel Le Cesne
Ho Yeong Lim, Jeong Heo, Tae‐You Kim, Wai Meng David Tai, Yoon‐Koo Kang, George Lau, Masatoshi Kudo, Won Young Tak, Magdalena Watras, S. Ali, Alejandra Negro, Ghassan K. Abou‐Alfa, Robin Kate Kelley
Discussion(0)
No comments yet. Be the first to comment.